


# Bispecific Antibodies Asia & Pacific



March 22, 2023

Digital Conference

1:00PM JST // 9:30AM IST // 12:00PM CST

## 1ST APPROVAL FOR THE DOMESTIC DEVELOPMENT OF A BISPECIFIC IN 2022: WHAT'S ON THE HORIZON FOR ASIA & PACIFIC BIOPHARMA?

Connect & Collaborate with Leaders in the Region to Transform your Immuno-Oncology Pipeline & Advance your Candidates into the Clinic

### THE FOREFRONT OF BISPECIFICS IN ASIA, PACIFIC & BEYOND

#### Design & Developability for Bispecifics

- Following the first **in-house approval**, what **R&D trends** can we expect in the **Asia & Pacific region**?
- Novel **antibody engineering** approaches for improved **targeting, specificity & avidity**
- Tackling & overcoming adverse **immunogenicity** without compromising on **efficacy**

#### The Next Generation of Bispecific Antibodies

- How are drug developers **diversifying** their **portfolios & pipelines** to remain at the forefront of bispecific research?
- Expanding beyond exhaustive **T-cell engager** approaches & utilising the whole **immuno-oncology toolbox**
- Learn from clinical **successes & failures** to inform intelligent drug design for bispecific antibody discovery

#### Analytical & CMC Considerations

- Innovative **screening** of **novel targets**, to accelerate **successful** discovery & development towards the **clinic**
- Ensuring effective **downstream processing & purification** for efficient & scalable **commercialization**
- Developing **bioanalytical strategies & technologies** for accurate **characterisation** of therapeutics

**#BISPECIFICANTIBODIES**



<b>22<sup>nd</sup> March</b> <b>1pm – 7pm JST</b>	<b>Bispecific Antibodies Asia &amp; Pacific Digital Conference</b>
<b>1:00pm</b>	<b>Welcoming Remarks</b>
<b>Discovery, Design and Development of Bispecifics for the Future of Safe and Effective Immunotherapy</b>	
<b>1:05pm</b>	<p><b>Panel: Current Trends and Future Outlooks in Bispecific Antibody R&amp;D</b></p> <ul style="list-style-type: none"> <li>• How can we fully expand the value of bispecifics?</li> <li>• Can we look beyond oncology?</li> <li>• Looking for new targets to address unmet needs</li> <li>• What are the current successes and how can we improve?</li> <li>• Should bioanalytical methods be developed alongside the drug product?</li> <li>• What to do when the bispecific doesn't show activity</li> </ul> <p><b>Michelle Xia, Founder, Chairwoman, President and CEO, Akeso, Inc. China</b>  <b>Changshou Gao, Senior Vice President &amp; Chief Technology Officer, Innovent Biologics, USA</b>  <b>Feng Wang, Director &amp; Senior Principal Scientist, Genentech, USA</b>  <b>Jaeho Jung, Executive Vice President, Head of Discovery, ABL Bio, Republic of Korea</b>  <b>Chengbin Wu, CEO, Shanghai EpimAb Biotherapeutics Co., Ltd, China</b>  <b>Jing Li, Founder &amp; CEO, VelaVigo, China</b></p>
<b>1:50pm</b>	<p><b>Antibody Engineering and Optimization for Improved Binding and Selectivity</b></p> <ul style="list-style-type: none"> <li>• Honing the combination of avidity and selectivity</li> <li>• Intelligent drug design to match the target</li> <li>• Augmenting the Fc region</li> </ul> <p><b>William Kelton, Senior Lecturer, The University of Waikato, New Zealand</b></p>
<b>2:20pm</b>	<b>Coffee Break &amp; Networking Opportunities on the ConnectMe Platform</b>
<b>The Next-Generation of Bispecifics: T-Cell Engagers and Beyond</b>	
<b>2:50pm</b>	<p><b>Innovative R&amp;D Platform and Technology for the Development of Successful Bispecifics</b></p> <ul style="list-style-type: none"> <li>• Research pipeline overview</li> <li>• Development of End-to-End platform with GMP-Manufacturing</li> <li>• Combination using bispecific as next-generation immuno-oncology backbone</li> </ul> <p><b>Baiyong Li, Co-Founder, Executive Vice President, CSO, Akeso, Inc. China</b></p>
<b>3:20pm</b>	<p><b>Diverse Portfolio of Bispecifics for a Range of Clinical Indications</b></p> <ul style="list-style-type: none"> <li>• BBB shuttle for CNS targeting</li> <li>• T-cell engagement and Immune modulation for oncological indications</li> <li>• Pipeline overview</li> </ul> <p><b>Weon-Kyoo You, Executive Vice President &amp; Chief Scientific Officer, ABL Bio, Inc., Republic of Korea</b></p>
<b>3:50pm</b>	<b>Coffee Break &amp; Networking Opportunities on the ConnectMe Platform</b>
<b>Upstream, Downstream, and Bioanalytical Considerations for the Commercialization of Bispecific Antibodies</b>	
<b>4:20pm</b>	<p><b>Spotlight Presentation - Molecular Projection: a Way for Top-down Characterization that Enables Observation of Biopharmaceutics without Prerequisite Information</b></p> <p><b>Takashi Sato, Deputy General Manager, Application Laboratories, Rigaku Corporation, Japan</b></p> 
<b>4:50pm</b>	<p><b>Scalable Downstream Processing for Bispecific Antibody Purification</b></p> <ul style="list-style-type: none"> <li>• Effective and innovative purification strategies for bispecific antibodies</li> <li>• Harness affinity capture step for product-related impurity removal</li> </ul>

	<ul style="list-style-type: none"> <li>• Wise selection of resins for polishing step development</li> </ul> <b>Wei Zhang, Senior Scientist &amp; DSP Group Head (Biotherapeutics Purification and Analytics), A*STAR Bioprocessing Technology Institute, Singapore</b>
<b>5:20pm</b>	<b>High-level Analytics for the Characterization of Bispecific Antibodies</b> <ul style="list-style-type: none"> <li>• Efficient analytic workflow development for bispecifics</li> <li>• Characterization and method optimization</li> <li>• Stability analysis</li> </ul> <b>Sourav Layek, Proteomics and Characterization of Novel Biologics and Biosimilars, Sun Pharma Advanced Research Company Ltd., India</b>
<b>5:50pm</b>	<b>End of Day/ Networking on the Platform</b>

## Want some more information?

### Booking & General Enquiries

Contact Ellie Farr at [Ellie.Farr@informa.com](mailto:Ellie.Farr@informa.com)

### Sponsorship Enquiries

Contact Kristen Schott at [Kristen.Schott@informa.com](mailto:Kristen.Schott@informa.com)

### Content & Speaker Enquiries

Contact Lottie Leinfellner at [Lottie.Leinfellner@informa.com](mailto:Lottie.Leinfellner@informa.com)

### Website

<https://informaconnect.com/bispecifics-asia/>